Octreotide long-acting repeatable in the treatment of neuroendocrine tumors: patient selection and perspectives

References

• ThulinLSamnegardHTydenGLongDHEfendicSEfficacy of somatostatin in a patient with carcinoid syndromeLancet1978312807943
   Google Scholar
• FrolichJCBloomgardenZTOatesJAMcGuiganJERabinowitzDThe carcinoid flush. Provocation by pentagastrin and inhibition by somatostatinN Engl J Med19782991910551057703771
   PubMed Web of Science ®Google Scholar
• BauerWBrinerUDoepfnerWSMS 201–995: a very potent and selective octapeptide analogue of somatostatin with prolonged actionLife Sci19823111113311406128648
   PubMed Web of Science ®Google Scholar
• ModlinIMLatichIKiddMZikusokaMEickGTherapeutic options for gastrointestinal carcinoidsClin Gastroenterol Hepatol20064552654716630755
   PubMed Web of Science ®Google Scholar
• LudlamWHAnthonyLSafety review: dose optimization of somatostatin analogs in patients with acromegaly and neuroendocrine tumorsAdv Ther2011281082584121964965
   PubMed Web of Science ®Google Scholar
• StrosbergJRBensonABHuynhLClinical benefits of above-standard dose of octreotide LAR in patients with neuroendocrine tumors for control of carcinoid syndrome symptoms: a multicenter retrospective chart review studyOncologist201419993093625096997
   PubMed Web of Science ®Google Scholar
• ChadhaMKLombardoJMashtareTHigh-dose octreotide acetate for management of gastroenteropancreatic neuroendocrine tumorsAnticancer Res200929104127413019846960
   PubMed Web of Science ®Google Scholar
• FerollaPFaggianoAGrimaldiFShortened interval of long-acting octreotide administration is effective in patients with well-differentiated neuroendocrine carcinomas in progression on standard dosesJ Endocrinol Invest201235332633121757992
   PubMed Web of Science ®Google Scholar
• KlimstraDSPathology reporting of neuroendocrine tumors: essential elements for accurate diagnosis, classification, and stagingSemin Oncol2013401233623391110
   PubMed Web of Science ®Google Scholar
• KlimstraDSBeltranHLilenbaumRBergslandEThe spectrum of neuroendocrine tumors: histologic classification, unique features and areas of overlapAm Soc Clin Oncol Educ Book20159210325993147
   PubMedGoogle Scholar
• YamaguchiTFujimoriTTomitaSClinical validation of the gastrointestinal NET grading system: Ki-67 index criteria of the WHO 2010 classification is appropriate to predict metastasis or recurrenceDiagn Pathol201386523607525
   PubMed Web of Science ®Google Scholar
• FaggianoACarratuACGuadagnoESomatostatin analogues according to Ki67 index in neuroendocrine tumours: an observational retrospective-prospective analysis from real lifeOncotarget2016755538554726701729
   PubMedGoogle Scholar
• RubinJAjaniJSchirmerWOctreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndromeJ Clin Oncol199917260060610080605
   PubMed Web of Science ®Google Scholar
• GarlandJBuscombeJRBouvierCSandostatin LAR (long-acting octreotide acetate) for malignant carcinoid syndrome: a 3-year experienceAliment Pharmacol Ther200317343744412562458
   PubMed Web of Science ®Google Scholar
• AnthonyLVinikAIEvaluating the characteristics and the management of patients with neuroendocrine tumors receiving octreotide LAR during a 6-year periodPancreas201140798799421697761
   PubMed Web of Science ®Google Scholar
• RinkeAMullerHHSchade-BrittingerCPROMID Study GroupPlacebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study GroupJ Clin Oncol200927284656466319704057
   PubMed Web of Science ®Google Scholar
• RinkeAWittenbergMSchade-BrittingerCPlacebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in Patients with Metastatic Neuro-endocrine Midgut Tumors (PROMID): Results of Long-Term SurvivalNeuroendocrinology20171041263226731483
   PubMed Web of Science ®Google Scholar
• YaoJCHassanMPhanAOne hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United StatesJ Clin Oncol200826183063307218565894
   PubMed Web of Science ®Google Scholar
• PavelMEHainsworthJDBaudinERADIANT-2 Study GroupEverolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 studyLancet201137898082005201222119496
   PubMed Web of Science ®Google Scholar
• YaoJCLombard-BohasCBaudinEDaily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trialJ Clin Oncol2010281697619933912
   PubMed Web of Science ®Google Scholar
• PavelMEBaudinEObergKEEfficacy of everolimus plus octreotide LAR in patients with advanced neuroendocrine tumor and carcinoid syndrome: final overall survival from the randomized, placebo-controlled phase 3 RADIANT-2 studyAnn Oncol20172871569157528444114
   PubMed Web of Science ®Google Scholar
• BajettaECatenaLFazioNEverolimus in combination with octreotide long-acting repeatable in a first-line setting for patients with neuroendocrine tumors: an ITMO group studyCancer2014120162457246324752410
   PubMed Web of Science ®Google Scholar
• TippeswamyRPatilSSateeshCTEverolimus plus octreotide long-acting repeatable in advanced neuroendocrine tumors in the routine tertiary cancer care setting: an Indian experienceIndian J Cancer201552335936226905137
   PubMed Web of Science ®Google Scholar
• CivesMStrosbergJRadionuclide therapy for neuroendocrine tumorsCurr Oncol Rep2017192928220446
   PubMed Web of Science ®Google Scholar
• KrenningEPKooijPPBakkerWHRadiotherapy with a radio-labeled somatostatin analogue, [111In-DTPA-D-Phe1]-octreotide. A case historyAnn N Y Acad Sci19947334965067978900
   PubMed Web of Science ®Google Scholar
• KwekkeboomDJde HerderWWKamBLTreatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survivalJ Clin Oncol200826132124213018445841
   PubMed Web of Science ®Google Scholar
• StrosbergJEl-HaddadGWolinEPhase 3 trial of 177Lu-Dotatate for midgut neuroendocrine tumorsN Engl J Med2017376212513528076709
   PubMed Web of Science ®Google Scholar
• BodeiLCremonesiMGranaCMPeptide receptor radionuclide therapy with (1)(7)(7)Lu-DOTATATE: the IEO phase I-II studyEur J Nucl Med Mol Imaging201138122125213521892623
   PubMed Web of Science ®Google Scholar
• SabetAEzziddinKPapeUFLong-term hematotoxicity after peptide receptor radionuclide therapy with 177Lu-octreotateJ Nucl Med201354111857186124009272
   PubMed Web of Science ®Google Scholar
• BodeiLKwekkeboomDJKiddMModlinIMKrenningEPRadiolabeled somatostatin analogue therapy of gastroenteropancreatic cancerSemin Nucl Med201646322523827067503
   PubMed Web of Science ®Google Scholar
• DeutschGBLeeJHBilchikAJLong-term survival with long-acting somatostatin analogues plus aggressive cytoreductive surgery in patients with metastatic neuroendocrine carcinomaJ Am Coll Surg20152211263626027502
   PubMed Web of Science ®Google Scholar
• YaoJCPhanAHoffPMTargeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2bJ Clin Oncol20082681316132318323556
   PubMed Web of Science ®Google Scholar
• ToumpanakisCGarlandJMarelliLLong-term results of patients with malignant carcinoid syndrome receiving octreotide LARAliment Pharmacol Ther200930773374019573169
   PubMed Web of Science ®Google Scholar
• BarrioMCzerninJFantiSThe impact of somatostatin receptor-directed PET/CT on the management of patients with neuroendocrine tumor: a systematic review and meta-analysisJ Nucl Med201758575676128082438
   PubMed Web of Science ®Google Scholar
• DeppenSALiuEBlumeJDSafety and efficacy of 68Ga-DOTATATE PET/CT for diagnosis, staging, and treatment management of neuroendocrine tumorsJ Nucl Med201657570871426769865
   PubMed Web of Science ®Google Scholar
• BuchmannIHenzeMEngelbrechtSComparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumoursEur J Nucl Med Mol Imaging200734101617162617520251
   PubMed Web of Science ®Google Scholar
• DeppenSABlumeJBobbeyAJ68Ga-DOTATATE compared with 111In-DTPA-octreotide and conventional imaging for pulmonary and gastroenteropancreatic neuroendocrine tumors: a systematic review and meta-analysisJ Nucl Med201657687287826769864
   PubMed Web of Science ®Google Scholar
• KrauszYFreedmanNRubinsteinR68Ga-DOTA-NOC PET/CT imaging of neuroendocrine tumors: comparison with 111In-DTPA-octreotide (OctreoScan®)Mol Imaging Biol201113358359320652423
   PubMed Web of Science ®Google Scholar
• AyatiNLeeSTZakaviSRSandostatin LAR therapy differentially alters 68Ga-DOTATATE uptake in normal tissues compared to primary tumors and metastatic lesionsJ Nucl Med Epub2017720
   Web of Science ®Google Scholar
• SiderisLDubePRinkeAAntitumor effects of somatostatin analogs in neuroendocrine tumorsOncologist201217674775522628056
   PubMed Web of Science ®Google Scholar
• ShenCShihYCXuYYaoJCOctreotide long-acting repeatable use among elderly patients with carcinoid syndrome and survival outcomes: a population-based analysisCancer2014120132039204924676892
   PubMed Web of Science ®Google Scholar
• ShenCShihYCXuYYaoJCOctreotide long-acting repeatable among elderly patients with neuroendocrine tumors: a survival analysis of SEER-Medicare dataCancer Epidemiol Biomarkers Prev201524111656166526315553
   PubMed Web of Science ®Google Scholar
• ShenCXuYDasariAShihYCYaoJCOctreotide LAR dosage and survival among elderly patients with distant-stage neuroendocrine tumorsOncologist201621330831326911407
   PubMed Web of Science ®Google Scholar
• LaskaratosFMWalkerMNaikKPredictive factors of antiproliferative activity of octreotide LAR as first-line therapy for advanced neuroendocrine tumoursBr J Cancer2016115111321132727811856
   PubMed Web of Science ®Google Scholar
• EjazSVassilopoulou-SellinRBusaidyNLCushing syndrome secondary to ectopic adrenocorticotropic hormone secretion: the University of Texas MD Anderson Cancer Center ExperienceCancer2011117194381438921412758
   PubMed Web of Science ®Google Scholar
• IliasITorpyDJPacakKMullenNWesleyRANiemanLKCushing’s syndrome due to ectopic corticotropin secretion: twenty years’ experience at the National Institutes of HealthJ Clin Endocrinol Metab20059084955496215914534
   PubMed Web of Science ®Google Scholar
• IsidoriAMKaltsasGAPozzaCThe ectopic adrenocorticotropin syndrome: clinical features, diagnosis, management, and long-term follow-upJ Clin Endocrinol Metabo2006912371377
   PubMed Web of Science ®Google Scholar
• de BruinCFeeldersRAWaaijersAMDifferential regulation of human dopamine D2 and somatostatin receptor subtype expression by glucocorticoids in vitroJ Mol Endocrinol2009421475618852217
   PubMed Web of Science ®Google Scholar
• de BruinCHoflandLJNiemanLKMifepristone effects on tumor somatostatin receptor expression in two patients with Cushing’s syndrome due to ectopic adrenocorticotropin secretionJ Clin Endocrinol Metab201297245546222090282
   PubMed Web of Science ®Google Scholar
• BanerjeeRRMarinaNKatznelsonLFeldmanBJMifepristone treatment of cushing’s syndrome in a pediatric patientPediatrics20151365e1377e138126459648
   PubMed Web of Science ®Google Scholar
• MoraitisAGAuchusRJMifepristone improves octreotide efficacy in resistant ectopic cushing’s syndromeCase Rep Endocrinol20162016845380126989527
   PubMedGoogle Scholar